Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Jump-Start Your Search For Promising Trade Ideas With Barchart Premier’s "Top Stock Pick". FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.

Thiogenesis Therapeutics Corp (TTIPF)

Thiogenesis Therapeutics Corp (TTIPF)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Help
Go To:
Thiogenesis to Present Clinical Updates in MELAS and Leigh Syndrome Spectrum at UMDF Bench-to-Bedside Webinar Newsfile - Mon Jan 5, 8:08AM CST

Dr. Rioux Will Present on Phase 2 MELAS Program & Upcoming Phase 2a Leigh Syndrome TrialSan Diego, California--(Newsfile Corp. - January 5, 2026) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF)...

TTI.VN : 0.600 (-7.69%)
TTIPF : 0.5834 (-0.27%)
Thiogenesis Therapeutics Expands on Plans for Phase 3 Pivotal Trial of TTI-0102 in Nephropathic Cystinosis Newsfile - Mon Nov 24, 2025

IND expected in early 2026; TTI-0102 designed to improve tolerability & simplify dosingSan Diego, California--(Newsfile Corp. - November 24, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX:...

TTI.VN : 0.600 (-7.69%)
TTIPF : 0.5834 (-0.27%)
Thiogenesis Reports Positive Interim Phase 2 Trial Results for MELAS and Announces Pipeline Advancements in Leigh Syndrome and Cystinosis Newsfile - Tue Nov 4, 2025

Trial achieved biological proof-of-concept, dose discovery and biomarker improvementSan Diego, California--(Newsfile Corp. - November 4, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF)...

TTI.VN : 0.600 (-7.69%)
TTIPF : 0.5834 (-0.27%)
Thiogenesis Announces Extension to Investor Relations Agreement Newsfile - Fri Oct 3, 2025

San Diego, California--(Newsfile Corp. - October 3, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (Thiogenesis or the Company) a clinical-stage biotechnology company developing disulfides that drive...

TTI.VN : 0.600 (-7.69%)
TTIPF : 0.5834 (-0.27%)
Thiogenesis Reports on 2025 Annual General Meeting of Shareholders and Provides Corporate Update Newsfile - Thu Sep 11, 2025

San Diego, California--(Newsfile Corp. - September 11, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biopharmaceutical company developing...

TTI.VN : 0.600 (-7.69%)
TTIPF : 0.5834 (-0.27%)
Thiogenesis Receives Confirmatory Guidance on IMPD for Pediatric MASH Phase 2a Clinical Trial in Europe and Core Patent Granted in EU Newsfile - Wed Jun 25, 2025

San Diego, California--(Newsfile Corp. - June 25, 2025) - Thiogenesis Therapeutics, Inc. (TSXV: TTI) (OTCQX: TTIPF), a clinical-stage biopharmaceutical company developing next-generation thiol-based therapies...

TTI.VN : 0.600 (-7.69%)
TTIPF : 0.5834 (-0.27%)
Thiogenesis Therapeutics to Present at UMDF's Mitochondrial Medicine 2025 Conference Newsfile - Fri Jun 20, 2025

Dr. Rioux to Highlight Industry-Leading Clinical Programs in MELAS and Leigh Syndrome SpectrumSan Diego, California--(Newsfile Corp. - June 20, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX:...

TTI.VN : 0.600 (-7.69%)
TTIPF : 0.5834 (-0.27%)
Thiogenesis Announces Second Site Begins Enrolling in Phase 2 MELAS Clinical Trial and Provides Update Newsfile - Tue Jun 17, 2025

San Diego, California--(Newsfile Corp. - June 17, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biopharmaceutical company developing...

TTI.VN : 0.600 (-7.69%)
TTIPF : 0.5834 (-0.27%)
Thiogenesis Announces Grant of Stock Options Newsfile - Thu Jun 12, 2025

San Diego, California--(Newsfile Corp. - June 12, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ("Thiogenesis" or the "Company") a clinical-stage biotechnology company developing disulfides...

TTI.VN : 0.600 (-7.69%)
TTIPF : 0.5834 (-0.27%)
Thiogenesis Announces FDA Clearance of its Investigational New Drug Application ("IND") for a Phase 2a Clinical Trial in Leigh Syndrome Spectrum Newsfile - Wed Jun 11, 2025

San Diego, California--(Newsfile Corp. - June 11, 2025) - Thiogenesis Therapeutics, Corp. (TSXV: TTI) (OTCQX: TTIPF) ('Thiogenesis' or the 'Company') a clinical-stage biotechnology company developing disulfides...

TTI.VN : 0.600 (-7.69%)
TTIPF : 0.5834 (-0.27%)

Barchart Exclusives

As Meta Delays New Ray-Ban Display Glasses, Should You Buy, Sell, or Hold META Stock? Barchart - Sat Jan 10, 2:19PM CST
Meta’s pause on the global rollout of its Ray-Ban Display smart glasses leaves investors to weigh whether META is a buy, sell, or hold at this pivotal moment. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot